Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Allogeneic Donor Lymphocyte Infusions Combined With Blinatumomab (DLI-TARGET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03982992
Recruitment Status : Recruiting
First Posted : June 12, 2019
Last Update Posted : June 14, 2019
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Christian Schmidt, Ludwig-Maximilians - University of Munich

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : May 31, 2021
Estimated Study Completion Date : November 30, 2021